SecBot SecBot
6-K ·Filed Jun 8, 2026

BNTX

BioNTech SE
NEUTRAL
Impact 4/10
Horizonmonths Processed5mo ago SEC0001776985-26-000041
Notable filing: 6-K
Actionable Insight • Neutral

Monitor execution pace and any subsequent financial reports for fundamental changes. The buyback may provide price support but does not alter the underlying business outlook. Watch for quarterly updates on repurchase activity.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$85.50
T+0 close · Jun 8, 2026 · via day close
Latest settled
+19.23%
T+60 · $101.95
Vs SPY
+16.18%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 8 $85.50entry
  2. T+1 · 5mo ago +1.17%α +1.46% · $86.50
  3. T+5 · 5mo ago +6.20%α +4.09% · $90.80
  4. T+20 · 4mo ago +9.86%α +8.23% · $93.93
  5. T+60 · 3mo ago +19.23%α +16.18% · $101.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioNTech announced the commencement of its previously authorized $1.0 billion share buyback program, effective June 8, 2026, through May 6, 2027. The program allows repurchase of up to 24.9 million ADSs (≈10% of share capital) via an independent credit institution, compliant with 10b-18/10b5-1 rules.

Key Facts

  • $1.0 billion share buyback program authorized on May 7, 2026, with buyback period June 8, 2026 to May 6, 2027.
  • Up to 24.9 million American Depositary Shares (ADSs) may be repurchased, representing approximately 10% of BioNTech's share capital.
  • Buyback will be executed by an independent credit institution in compliance with EU MAR and SEC Rules 10b-18 and 10b5-1.
  • Repurchased ADSs may be used for ordinary course obligations and to enhance capital efficiency.

Financial Impact

The $1.0 billion buyback represents approximately 4.5% of BioNTech's $22.1B market cap. Potential EPS accretion if fully executed, but no immediate financial impact.

share counteps

Risk Factors

  • Buyback may not be fully executed due to market conditions or corporate decisions.
  • Underlying business fundamentals (e.g., COVID vaccine demand) could deteriorate, offsetting any buyback benefits.
  • Regulatory or legal constraints could limit repurchase activity.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
81% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001776985-26-000041
Document: a991june2026sbbarticle51ma.htm0001776985-26-000041
Document: 0001776985-26-000041-index-headers.html0001776985-26-000041
Document: 0001776985-26-000041-index.html0001776985-26-000041
Document: 0001776985-26-000041.txt0001776985-26-000041

Track record

38 reports on BNTX

Performance horizon

5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
  2. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  3. Nov 3, 202613d ago 6-K Neutral 5/10 No price data
  4. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
  5. Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
  6. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  7. Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  8. Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
  9. Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
  10. Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 8, 2026